Quidel Q3 Revenues Narrow Slightly; MDx Initiatives Remain on Track | GenomeWeb

NEW YORK (GenomeWeb News) – Quidel said after the close of the market Tuesday that revenues in the third quarter narrowed by a fraction of 1 percent year over year, missing the consensus Wall Street estimate.

Company officials also said that the firm's plans for its molecular diagnostic products remain on schedule.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.